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Angiopoietin 2 (Ang2) is a secreted glycoprotein upregulated at sites of angiogenesis and has been implicated in
cancer neovascularization. Recent studies have suggested efficacy of combined Ang and vascular endothelial
growth factor receptor (VEGFR) inhibition for patients with metastatic renal cell carcinoma (mRCC). We measured
Ang2 expression in human tissue and plasma, and tested the effect of dual Ang1/2 (trebananib; AMG386) or Ang2
alone (L1-7) inhibition with VEGFR inhibition on murine RCC growth and blood flow. Ang2 levels were higher in
human tumors than normal tissues with RCC ranking highest for Ang2 expression across all tumor types tested.
Plasma Ang2 was significantly higher in patients with mRCC compared to controls or patients with stage I disease.
Plasma Ang2 decreased with sunitinib treatment and increased at time of disease progression. In the RCC mouse,
dual Ang1/2 and Ang2 inhibition improved the activity of sunitinib. Combined Ang1/2 and VEGFR inhibition
prevented the resumption of blood flow associated with sunitinib resistance. Thus, Ang2 inhibition, independent
of Ang1 inhibition, improves the activity of sunitinib and plasma Ang2 increases in the setting of progression on
sunitinib possibly contributing to resistance. Further, arterial spin-labeled perfusion magnetic resonance imaging
might be a non-invasive marker of the antiangiogenic activity of Ang inhibitors.
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Vascular endothelial growth factor receptor (VEGFR) inhibition has
shown significant antitumor and antiangiogenic activity in patients
with renal cell carcinoma (RCC). Agents such as sunitinib, sorafenib,
pazopanib, and axitinib have all shown activities in patients with
metastatic RCC [1-4] leading to Food and Drug Administration
approval. However, antiangiogenic therapy with VEGFR tyrosine
kinase inhibitors (TKIs) does not lead to durable or complete responses
and treatment resistance develops at a median of 9 to 12 months.
Resistance could be associated with selection of tumor cells that
can survive treatment-induced hypoxia or through activation of
angiogenic pathways parallel to the VEGF axis. We have shown that
resistance to therapy is associated with resumption of angiogenesisdespite continued therapy, consistent with the activation of alternate
angiogenic pathways [5,6]. Others have implicated angiogenic
factors, such as interleukin 8 and fibroblast growth factor in
resistance [7,8]. One additional pathway that has recently been the
Table 1. The List of Primers Used in the Gene Expression Studies by RT-PCR.
Forward Primer Reverse Primer Probe
Ang1 GGA GGA TGG TGG TTT GAT GC TGG TTT TGT CCC GCA GTA TAG A b6FAMNTG TGG CCC CTC CAA TCT AAA TGG AAT GbTAMN
Ang2 TAC ACT TTC CTC CTG CCA GAG AT TGC ACA GCA TTG GAC ACG T b6FAMNCA ACT GCC GCT CTT CCT CCA GCC bTAMN
CD31 CGG TGC AAA ATG GGA AGA A TGA CGT GAG AGG TGG TGC TG b6FAMNTG ACC CTG CAG TGC TTC GCG GbTAMN
VEGFR2 GAC AGA GGG ACT TGG ACT GGC CTC AGT CAC CTC CAC CCT TTG b6FAMNTG GCC CAA TAA TCA GAG TGG CAG TGA bTAMN
VEGF GGG CAG AAT CAT CAC GAA GTG GGT CTC GAT TGG ATG GCA GT b6FAMNTG AAG TTC ATG GAT GTC TAT CAG CGC AGC bTAMN
able 2. Characteristics of Patients Included in the Plasma Studies.
atient Characteristics Sunitinib (N = 44)
ge 57 (Median) 41-76 (Range)
ender Number Percentage
M 31 70.5
F 13 29.5
revious nephrectomy Number Percentage
Y 39 88.6
N 5 11.4
ntiangiogenic drug Number Percentage
Sunitinib 42 95.5
Sorafenib 1 2.3
Pazopanib 1 2.3
rior line(s) of treatment Number Percentage
1 12 27.3
2 16 36.4
3 11 25.0
4 4 9.1
5 0 0
6 1 2.3
rior treatment Number Percentage
IL-2 20 45.5
Avastin 13 29.5
Sorafenib 12 27.3
Pazopanib 2 4.5
Axitinib 3 6.8
mTOR inhibitor** 2 4.5
Clinical trial 9 20.5
Other 4 9.1
* Of the 39 patients who had prior Nx, 24 had cytoreductive nephrectomy. All patients were treated
ith VEGFR TKI for metastatic disease and not in the adjuvant or neoadjuvant setting.
** Mammalian target of rapamycin.
Translational Oncology Vol. 7, No. 2, 2014 Ang2 Inhibition Augments VEGFR Inhibition in RCC Wang et al. 189subject of much investigation is the angiopoietin (Ang) axis. Ang2
inhibition has been shown to have activity in preclinical models and
several agents are currently being tested in clinical settings across
multiple tumor types [9-12]. While much is known about the role of
Ang2 in cancer, several important unanswered questions exist. Ang1
and Ang2 are endothelial-secreted proteins with a complex
relationship and potentially competing overall effects on tumor
angiogenesis. Ang2 is most commonly described as a molecule that
destabilizes vascular networks, supporting neoangiogenesis [13,14].
Ang1 binds to the Tie2 receptor to promote vascular maturation,
inhibiting angiogenesis. Ang2 is an antagonist of Ang1 signaling
through Tie2. Thus, one of the key questions in the Ang field is
whether, in RCC, Ang1 inhibition undermines or augments effects
of Ang2 inhibition.
In previous studies, the Ang2-specific inhibitor L1-7, Ang2-CovX
bodies, and the Ang2 antibody 3.19.3 slowed the growth of colon
and lung cancer xenografts and accentuated the activity of VEGF
pathway inhibitors [10,15,16]. The dual Ang1/2 inhibitor, trebana-
nib (AMG386), was found to have more activity than Ang2-specific
inhibitors alone in colon cancer models [9]. Falcón et al. described
similar findings in a colon cancer model and showed that Ang1
inhibition augmented the effect of Ang2 inhibition by preventing
vascular normalization seen with the Ang2 inhibitor [13]. RCC is
typified by Von Hippel–Lindau (VHL) loss leading to exquisite
dependency on the VEGF-driven angiogenesis. As a consequence,
RCC exposure to VEGF pathway inhibitors has been shown to result
in “vascular infarction” rather than vascular normalization. Given this
distinct biology, we sought to determine the relative effects on tumor
growth and perfusion of Ang1, Ang2, and dual Ang1/2 inhibition
alone and in combination with VEGF pathway inhibitors in a mouse
model of RCC.
Another key question related directly to the clinical development
of Ang inhibitors is how to select the patients most likely to benefit
from this treatment. Currently, there is little data to guide optimal
patient selection and determine the optimal treatment setting. To
explore the possibility that Ang2 may be a useful surrogate or predictive
marker of activity in RCC, we measured Ang2 plasma levels in patients
with RCC either at presentation or during the course of VEGFR-
targeted therapy. Taken together, these data inform the continued
exploration of Ang2 inhibitors such as trebananib in patients with RCC
or other cancers.
Materials and Methods
Evaluation of Gene Expression by Reverse
Transcription–Polymerase Chain Reaction
Frozen tumor specimens of several human tumor types and non-
malignant renal tissues, including non-malignant kidney tissue (cortex
and medulla from non-oncology patients), clear cell RCC (ccRCC)
tissue, and other non-renal tumor tissue including bladder, lym-
phoma, lung (adeno), lung (squamous), laryngeal, ovarian, prostate,gastric, breast, colorectal, and pancreatic tumors, were obtained. Total
RNA was obtained either directly from a vendor (Ardais Corporation,
Lexington, MA) or extracted from frozen tissue samples (Zoion
Diagnostics Inc, Shrewsbury, MA) with the Qiagen RNeasyMini Kit.
All the RNA samples were treated with RNase-free DNase to remove
genomic DNA before reverse transcription–polymerase chain reaction
(RT-PCR). Quantitative RT-PCR was performed with 100 ng of total
RNA in duplicate with a TaqMan EZ RT-PCR Kit from Roche
(Indianapolis, IN). The primers and probes used in this study are listed
in Table 1. In vitro transcripts of cDNA fragments for each gene were
used as standard for calculating mRNA copy numbers. Cyclophilin A
mRNA copy number was used for normalization.
Plasma Ang2 Measurement
Circulating Ang2 levels were measured in plasma collected from 50
patients with metastatic RCC, 39 patients with stage I RCC before
nephrectomy, and 26 healthy volunteers. All 89 patients with RCC
had histologically confirmed RCC (99% ccRCC, n = 88), and all
provided written informed consent for sample collection. Samples
were collected from healthy volunteers not being seen in any specialty
clinics and who had no RCC pathology or urologic issues. Approval
for the RCC sample collection protocol was obtained from the
Institutional Review Board of the Dana-Farber/Harvard CancerT
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metastatic disease who were treated with sunitinib was collected.
Characteristics for the metastatic RCC cohort are listed in Table 2.
These patients received 50 mg of sunitinib daily for the first 4 weeks
(~28 days) of 6-week cycles until disease progression was documented
per response evaluation criteria in solid tumors criteria. Blood samples
were collected in sodium citrate tubes at baseline, approximately 4
weeks into treatment (median day 34.5), and at the time of disease
progression. Samples were centrifuged at 1500 rpm for 10 minutes
within 60 minutes of collection. Plasma samples were stored at −
80°C. Plasma Ang2 concentration was measured by ELISA (R&D
Systems, Minneapolis, MN).
Cell Culture
A498, a VHL-deficient human RCC cell line, was obtained from
the American Type Culture Collection (ATCC,Manassas, VA). Fresh
frozen aliquots were used for each experiment. A498 cells were grown
in Eagle's minimum essential medium. All media were supplemented
with 2 mM L-glutamine, 10% fetal calf serum, and 1% streptomycin
(50 μg/ml), and cells were cultured at 37°C with 5% CO2.
Tumor Xenograft Induction
For subcutaneous xenograft tumor models, female athymic nude/
beige mice (Charles River Laboratories, Wilmington, MA) were used.
All experiments were approved by the Institutional Animal Care and
Use Committee at Beth Israel Deaconess Medical Center. The mice
were housed and maintained in laminar flow cabinets under specificFigure 1. RT-PCR analysis of multiple tumor types shows that Ang2, VE
ccRCC versus other tumor types (bladder, lymphoma, lung, laryng
tumors). Ang2 and VEGF are also highly expressed in ccRCC versus n
**P b 0.01, ***P b 0.001.pathogen-free conditions, and throughout the entirety of the study,
all efforts were made to minimize suffering.
A498 cells were harvested from subconfluent cultures by a brief
exposure to 0.25% trypsin and 0.02% EDTA. Trypsinization was
stopped with medium containing 10% FBS, and the cells were
washed once in serum-free medium and resuspended in phosphate-
buffered saline as vehicle. Only suspensions consisting of single cells
with greater than 90% viability were used for the injections.
To establish RCC tumor xenografts, A498 tumor cells were
injected subcutaneously (1 × 107 cells) into the flanks of 6- to
8-week-old mice that were of 20 g average body weight. Tumors
developed in N80% of mice and were usually visible within a few
days of implantation. Once they reached a diameter of 3 to 5 mm,
tumors were measured daily with calipers to ensure a consistent size
at the outset of treatment. Treatment was initiated when the tumors
had grown to a diameter of 12 mm as previously described [6]. For
the single agent study, mice were randomized to the following
treatment arms: Fc control, mL4-3, L1-7, trebananib. For the
combination study, the arms were given as follows: Fc control,
sunitinib, trebananib, trebananib + sunitinib, sunitinib + L1-7, and
sunitinib + mL4-3. The dosing and schedule of treatment are given
as follows: sunitinib (53.6 mg/kg) was administered 6 of 7 days per
week by gavage. Human Fc (2.8 mg/kg, twice weekly), Ang1 inhibitor
mL4-3 (20 mg/kg, daily), Ang2 inhibitor L1-7 (2.8 mg/kg, twice
weekly), and dual Ang1/2 inhibitor (AMG386, trebananib) (2.8mg/kg,
twice weekly) were injected subcutaneously. Tumor long axis and short
axis were measured daily. Tumor volume was calculated by theGF, Ang1, VEGFR2, and CD31 are highly expressed in patients with
eal, ovarian, prostate, gastric, breast, colorectal, and pancreatic
ormal kidney tissue. Data are expressed as means ± SD. *P b 0.05,
Figure 2. Analysis of Ang2 levels in patient plasma. (A) Patients with
metastatic RCC have higher circulating plasma Ang2 levels than
patients with (low burden) stage 1 RCC or healthy controls (***P b
0.001). (B) Plasma analysis in patients at baseline prior to treatment
with sunitinib, ~day 28 after starting sunitinib, and at the time of
progression on sunitinib shows that Ang2 levels decrease with
sunitinib treatment and increase at the time of disease progression
(**P b 0.01 for both comparisons). Data are expressed asmeans±SD.
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curves. Treatment was continued until tumors grew to 20 mm
(i.e., the maximum allowable growth by Institutional Animal Care
and Use Commitee) or roughly day 50, at which point the mice
were killed.
Tumor Perfusion Imaging
Tumor perfusion imaging with arterial spin-labeled magnetic
resonance imaging (ASL MRI) was performed as previously
described [5,17,18] and quantified using standard methods [19]. A
single transverse slice of ASL was carefully positioned at the center of
the tumor, which was marked on the skin with a permanent marker
pen for follow-up MRI studies. To determine tumor perfusion, a
region of interest was drawn freehand around the peripheral margin
of the tumor by using an electronic cursor on the reference image
that was then copied to the perfusion image. The mean blood flow
for the tumor tissue within the region of interest was derived.
Statistical Analysis
Statistical significance was calculated for the plasma analysis by
Wilcoxon sign rank test for paired data and Wilcoxon rank sum
for unpaired data. Tumor growth curves are presented with mean
tumor volume ± standard error. Tumor perfusion comparisons
were performed using a Student's t-test. P b 0.05 was considered
significant.
Results
Ang2 Expression Is Elevated in Patients with RCC
Expression of Ang2 and other angiogenic genes including Ang1,
VEGF, VEGFR2, and CD31was analyzed by RT-PCR from samples of
non-malignant kidney tissue (n = 4), ccRCC tissue (n = 16), and other
non-renal tumor tissue including bladder, lymphoma, lung (adeno),
lung (squamous), laryngeal, ovarian, prostate, gastric, breast, colorectal,
and pancreatic tumors (n = 133; Figure 1). Ang2 expression levels in
ccRCC were 6.3-fold higher than in all other tumor types (P b 0.001).
Ang2 expression in ccRCC was 11.3-fold higher than in normal kidney
tissue (P = 0.0074). Ang1 expression levels in RCC and in other tumor
types were lower than in normal kidney tissue (P b 0.001).
VEGF, VEGFR2, and CD31 gene expression levels were all higher
in ccRCC than in other tumors (8.4-fold for VEGF, P b 0.001; 6.3-
fold for VEGFR2, P b 0.001; and 4.0-fold for CD31, P b 0.001;
Figure 1). VEGF gene expression level was 3.4-fold higher in ccRCC
than in normal kidney (P = 0.0499).
Plasma Ang2 Is Elevated in Patients with RCC
Plasma Ang2 was significantly higher in patients with metastatic
RCC (n = 50; median 3720 pg/ml; range [1010, 29,006]) compared
to plasma from healthy controls (n = 26; median 2255 pg/ml; [664,
6545]) and patients with stage I disease (n = 39; median 1394 pg/ml;
[520, 7784]; P b 0.001; Figure 2A). Characteristics for the metastatic
RCC cohort are shown in Table 2. Ang2 levels were also measured in
patients at baseline, approximately day 29 (median day 34.5) after
sunitinib initiation and at the time of disease progression on suni-
tinib. Plasma Ang2 levels decreased on sunitinib therapy (n = 39 pairs;
median baseline 3387 pg/ml, range [1010, 14149], median on
sunitinib (day 29) 1721 pg/ml; [325, 6584], P b 0.01) and increased
from day 29 at the time of disease progression (n = 28 pairs; 2654.56
pg/ml; [1284, 10555]; P b 0.01; Figure 2B). Of the patients withbaseline and day 29 samples, 5 of the 39 (13%) had dose modifica-
tions during this period and of the 28 patients in the day 29/
progression group, 7 (25%) had dose modifications during the time
they were on therapy.
Ang Inhibition Slows RCC Tumor Growth In Vivo
The effects of single agent mL4-3 (Ang1 inhibitor), L1-7 (Ang2
inhibitor), and trebananib (Ang1/2 inhibitor) were assessed on A498
RCC tumor growth. As single agents, trebananib and L1-7 slowed
A498 RCC tumor growth compared to Fc control. mL4-3 showed
little effect on A498 RCC tumor growth (Figure 3A).
To assess the impact of Ang inhibition on tumor perfusion, ASL
MRI was performed on three or more tumors in each group at
baseline, 1 and 3 weeks after treatment. A significant reduction in
tumor perfusion was observed after trebananib or L1-7 treatment but
not mL4-3 compared to Fc control group at day 7 (Fc: 142.9 ± 17.5
ml/100 g per min vs L1-7: 50.6 ± 23.6 ml/100 g per min, P = 0.006;
vs trebananib: 60.2 ± 22.8 ml/100 g per min, P = 0.008; vs mL4-3:
113.1 ± 24.8 ml/100 g per min, P = 0.204) and day 21 (Fc: 88.4 ±
40.9 ml/100 g per min vs L1-7: 28.1 ± 7.3 ml/100 g per min, P =
0.049; vs trebananib: 37.8 ± 11.3 ml/100 g per min, P = 0.029; vs
mL4-3: 68.4 ± 14.5 ml/100 g per min, P = 0.566; Figure 3, B
(representative images) and C). This is consistent with previous
reports that Ang2 blockade inhibits tumor angiogenesis in other
tumor models [9,20].
Trebananib Potentiates the Antitumor Effects of Sunitinib on
RCC Xenograft Tumor Growth and Perfusion
Sunitinib is an established treatment for patients with RCC;
however, despite initial responses, resistance develops in all patients.
Figure 3. Single agent effect on A498 RCC xenograft tumor growth and perfusion. (A) This figure shows that trebananib (Ang1/2 inhibitor)
and L1-7 (Ang2 inhibitor) slow A498 RCC tumor growth. Ang1 inhibition (mL4-3) did not alter A498 RCC tumor growth. (B, C)
Representative ASL MRI images and quantitative tumor perfusion results in A498 RCC xenograft tumor model at days 0, 7, and 21 after
treatment with trebananib (Ang1/2 inhibitor), L1-7 (Ang2 inhibitor), mL4-3 (Ang1 inhibitor), or Fc demonstrate significant reduction of
tumor perfusion observed after Ang2 inhibition but not Ang1 inhibition alone compared with the Fc group at days 7 and 21 (¶P b 0.05).
Data are expressed as means ± SD. Tumor regions are outlined with a red line in reference proton density images and corresponding ASL
perfusion color maps. The tumor size (mm) and the mean blood flow (in ml/100 g per min) are shown below the images. The color bar
beside the images represents the range of perfusion values from 0 to 160 ml/100 g per min.
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and VEGFR inhibition with sunitinib (Figure 4). In the A498 tumor
model, trebananib and L1-7 improved the antitumor activity of
sunitinib to a similar extent (Figure 4A). However, mL4-3 did not
enhance the tumor growth control of sunitinib.
To investigate the effects of sunitinib alone or in combination with
trebananib, L1-7, or mL4-3 on tumor perfusion, ASL MRI was
performed at baseline and 1, 3, and 7 weeks after treatment. Thecombination of sunitinib with either Ang2 inhibitor (trebananib or
L1-7) prevented the resumption of perfusion seen in tumors treated
with sunitinib alone at around day 50 after treatment (Figure 4, B
(representative images) and C). Tumor perfusion in both the com-
bination arms of sunitinib + trebananib or sunitinib + L1-7 was lower
than in the sunitinib arm at day 50 (sunitinib + Fc: 36.7 ± 15.0 ml/
100 g per min vs sunitinib + trebananib: 18.4 ± 11.1 ml/100 g per
min; vs sunitinib + L1-7: 16.0 ± 7.3 ml/100 g per min, P b 0.001).
Figure 4. Combination studies of trebananib, L1-7, and mL4-3 with sunitinib on RCC xenograft tumor growth and perfusion. (A) Both
trebananib and L1-7 improved the activity of sunitinib to a similar extent. mL4-3 did not improve sunitinib activity. (B) Representative ASL
MRI perfusion images show tumor perfusion results at baseline (pretreatment), 1 week, 3 weeks, and 7 weeks after treatment with
sunitinib + Fc, sunitinib +mL4-3, sunitinib + L1-7, and sunitinib + trebananib. Combination treatment of sunitinib and L1-7 or trebananib
prevented or delayed the resumption of tumor perfusion compared to sunitinib + Fc treatment. Trebananib and L1-7 had similar effects
on tumor perfusion reduction and prevention of tumor perfusion resumption with sunitinib treatment alone. Tumor regions are outlined in
red in ASL perfusion images (right column of each time point) and the corresponding reference proton density images (left column). The
tumor size (in mm) and mean blood flow (in ml/100 g per min) are shown below each image. The color bar beside the images represents
the range of perfusion values from 0 to 160 ml/100 g per min. (C) Bar graph demonstrating the quantification of ASL MRI tumor perfusion
at the time of resistance to sunitinib (~day 50 after treatment). The combination of sunitinib and either trebananib or L1-7 prevented the
restoration of tumor perfusion observed with sunitinib alone at the time of resistance (**P b 0.001).
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not single agent Ang1 inhibition) may suppress alternate angiogenic
pathways active in the setting of VEGFR inhibition.
Discussion
We have studied several aspects of Ang2 biology as it relates to RCC.
We showed that Ang2 is highly expressed in RCC versus other
tumor types and that patients with metastatic RCC have high Ang2
levels that decrease with sunitinib treatment and frequently increase
at the time of tumor resistance. We also showed in RCC mouse
models that Ang2 inhibition combined with VEGFR inhibitionslows tumor progression independent of Ang1 inhibition and that
inhibition correlates with tumor blood flow as measured by MR-
based perfusion imaging.
Our data suggest that the relative expression of Ang2 may vary
across multiple tumor types. Given the activity of Ang2 inhibitors in
RCC xenografts, it is tempting to hypothesize that the relative ex-
pression of Ang2 in a tumor might predict for sensitivity to Ang2
inhibition. This would further suggest that bladder cancer, being
also a strong Ang2 expressor, would also be predicted to benefit from
Ang2 inhibition. ccRCC also exhibited high levels of CD31,
VEGFR2, and VEGF expression in addition to Ang2, possibly
194 Ang2 Inhibition Augments VEGFR Inhibition in RCC Wang et al. Translational Oncology Vol. 7, No. 2, 2014contributing to the beneficial effect of combined sunitinib and Ang2
inhibition in delaying both disease progression and restoration of
perfusion in RCC xenografts models. One limitation of this study
is that we have not described the exact mechanism for the combi-
natorial effect on tumor perfusion. Further studies of the relationship
of VEGF and Ang2 in tumor angiogenesis in vivo are needed. The
necessity of VEGF pathway expression for sensitivity to Ang2 in-
hibitors either alone or in combination with VEGF inhibitors could
also be investigated in other tumors such as bladder cancer.
In this study, we confirmed earlier findings that plasma Ang2
levels are increased in patients with RCC and that these levels
decrease in patients with advanced RCC on treatment with sunitinib.
Our results suggest that Ang2 may be a surrogate marker for angio-
genic capacity of a tumor and may be a marker of endothelial
burden. As endothelial cells are the target of VEGF blocking therapy,
Ang2 levels may also correlate with the activity of VEGF pathway
inhibitors. Larger studies are needed to explore these hypotheses.
We also showed that Ang2 levels increase at a time when RCC
becomes resistant to sunitinib therapy. The hypothesis that Ang2
levels correlate with tumor angiogenic activity is further supported by
the data that Ang2 levels increase in a majority of patients at the time
of disease progression. Previous studies have shown that resistance to
VEGFR TKI therapy is in part due to “angiogenic escape” or renewed
angiogenesis that may be independent of VEGF [5,21]. We hypoth-
esize that the rise in Ang2 seen at the time of disease resistance to
VEGFR TKI therapy is a marker of resumed tumor angiogenesis.
This raises the possibility that an Ang2 inhibitor might demonstrate
activity in the setting of VEGFR TKI–resistant RCC. Not all patients
exhibited elevated Ang2 at the time of disease progression, raising the
possibility that increased Ang2 might predict for subsequent response
to Ang inhibition. As Ang2 inhibitors are in the clinic, this hypothesis
could be prospectively evaluated in clinical trials. Consistent with our
previous studies, the current study demonstrated that ASL MRI has
great practical potential as a non-invasive marker for monitoring
tumor angiogenesis without introducing any extrinsic contrast agents
[5,6,17,18]; others have shown that dynamic contrast-enhanced MRI
may also be useful for monitoring therapy [22].
Trebananib is a dual Ang1/2 inhibitor that antagonizes Tie2
signaling by binding to and sequestering Ang1 and Ang2. Trebananib
has been tested in several phase I and II clinical trials [23,24], and three
phase III trials are ongoing in ovarian cancer (TRINOVA-1,
TRINOVA-2, and TRINOVA-3). TRINOVA-1, evaluating treba-
nanib plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian
cancer, was recently reported to have met its primary end point of
progression-free survival (hazard ratio = 0.66, P b 0.001) [25].
Recent work suggests that Ang1 inhibition augments Ang2 inhibi-
tion in certain settings, but none of these studies were performed in
models of RCC [9,13,20]. We found that in a VHL-deficient RCC
model, Ang1/2 dual inhibition showed the same activity as the Ang2
alone inhibition. Thus, our data support the hypothesis that in RCC,
either Ang2 or combined Ang1/Ang2 inhibition may be effective
in combination with VEGFR inhibition in the clinical setting.
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